With the rapid development of China's pharmaceutical industry and the continuous optimization of pharmaceutical policies, pharmacoeconomic evidence now plays an increasingly important role in multiple scenarios such as the formulation of pharmaceutical policies, health insurance access, drug pricing, and reimbursement decisions. Meanwhile, artificial intelligence continues to rise in popularity, and its application in real-world research is gradually gaining attention from scholars and further contributing to the development of high-quality pharmacoeconomic value evidence. The International Pharmaceutical Business School of China Pharmaceutical University (IPBS) has invited Assistant Professor Tianze Jiao from the University of Florida to share his latest research results and practical experience. All are welcome to attend!
The information about the event is as follows:
Presentation Topic: Causal AI: Comparison of Percutaneous Left Ear Occlusion and Anticoagulants in the Real World
Event Time: Tuesday, June 25, 2024, 10:00am-12:00pm
Venue: Lecture Hall 111, Economics and Management Building
Reporter: Assistant Professor Tianze Jiao
Host: Associate Professor Li Hongchao
Reporter Profile:
Tianze Jiao is an Assistant Professor at the University of Florida and a renowned pharmacoepidemiologist with a focus on cardiovascular and cardiometabolic diseases. Assistant Professor Tianze Jiao conducts precision medicine-related research using large-scale databases (e.g., medical e-health data, insurance data) and advanced methods (e.g., causal inference, machine learning), which include: (1) identifying and resolving temporal biases in real-world data, (2) evaluating the comparative efficacy/safety and heterogeneity of therapeutic regimens, and (3) investigating drug-drug interactions, among others. Several studies conducted have been funded by the American Heart Association, CDC, Gates Foundation, and the Canadian Institutes of Health Research.
Facilitator Bio:
Hongchao Li, Doctor of Science, Associate Professor, M.S. Supervisor, Visiting Scholar at China Pharmaceutical Economics Research Center, Peking University, and Visiting Scholar at Department of Clinical Epidemiology and Biostatistics, McMaster University, Canada. He is the deputy director of the Pharmacoeconomics Evaluation Research Center of China Pharmaceutical University, the deputy director of Jiangsu Comprehensive Drug Evaluation Technology Center, a member of the Pharmacoeconomics Committee of China Pharmaceutical Society, a deputy director of the Pharmacoeconomics and Drug Evaluation Committee of China Association for the Promotion of Traditional Chinese Medicine Research, a deputy director of the Pharmacoeconomics Committee of China Association of Traditional Chinese Medicine, a standing member of the Pharmacoeconomics Committee of China Society of Research Hospitals, and an executive member of China Association of Pharmaceutical Biotechnology. He is a member of the Pharmacoeconomics Committee of the Chinese Society for the Promotion of Chinese Medicine, Vice Chairman of the Pharmacoeconomics Committee of the Chinese Society of Traditional Chinese Medicine, Vice Chairman of the Pharmacoeconomics Committee of the Chinese Society of Research Hospitals, Chairman of the Health Technology Evaluation Branch of the China Pharmaceutical and Biotechnology Association, Secretary General of the Pharmacoeconomics Committee of the Pharmaceutical Society of Jiangsu, Vice Chairman of the Pharmacists Association of Jiangsu Province, and the Research Committee of Pharmacist Evaluation and Policy Research of Jiangsu Province.
